BOSTON and WASHINGTON, July 2, 2012 /PRNewswire/ -- Leading whistleblower law firm Grant & Eisenhofer has represented one of several key whistleblowers behind a $1.04 billion settlement announced today between drug maker GlaxoSmithKline and the U.S. Department of Justice stemming from alleged marketing abuses of various GSK medications. Grant & Eisenhofer's client, Lois Graydon, is a nursing professional and former GSK Therapeutic Sales Manager.
The U.S. Attorney's office in Boston led the investigation into promotional tactics behind a total of nine GSK drugs. An accompanying criminal component of the case is expected to substantially increase the sum of the recovery.
Grant & Eisenhofer partner Reuben Guttman and senior counsel Traci Buschner are counsel to Lois Graydon, a registered nurse. She is one of the "relators" who alleged that GSK made false and misleading statements about Advair's safety and efficacy, thus enabling false or fraudulent claims to Medicare, Medicaid, and other reimbursement programs.
Advair's share of the recovery – more than $700 million – amounts to over half of the total civil settlement of $1.04 billion.
"The False Claims Act plays an important role in health industry compliance enforcement; health care is an issue that touches everyone and oversight, diligence and transparency are critical," said Mr. Guttman, one of the country's leading whistleblower attorneys.
"It is important that the medical community pays attention to this settlement and others and asks critical questions about the scientific support for the use of prescription drugs," he added.
"In this election year, the safety of pharmaceuticals and their cost to the health care system should be front and center," Mr. Guttman said.
He added, "Whistleblowers play an important role in compliance enforcement of our laws. We were proud to have represented one of the whistleblowers on this
|SOURCE Grant & Eisenhofer P.A.|
Copyright©2012 PR Newswire.
All rights reserved